TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06293794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Clinical Decision Support (CDS)
Description: The personalized CDS intervention evaluates clinician past prescribing patterns to determine whether prescribing misconceptions might exist and then conditionally present information to address those misconceptions. This is done through a nudge in the electronic health record that addresses common prescribing misconceptions for heart failure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Clinical Decision Support (CDS)
Description: The traditional CDS is the usual care intervention, which is patient-specific but are not clinician-specific.
Study: NCT06054178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium
Description: Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg
Study: NCT05023486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-G2-044 Monotherapy
Description: 1600 mg QD, 2000mg QD, and 2100 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Therapy
Description: previously initiated per standard of care, at a dose and frequency in accordance with the package insert
Study: NCT05208515

Intervention type: OTHER
Group type: OTHER
Intervention: general operating center
Description: send emergency cesarean section needing women from labor room to general operating center
Study: NCT05468190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT05517083

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultarthin bronchoscopy with intratumoral washing
Description: Each subject with NSCLC will undergo bronchooscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
Study: NCT04823702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldafermin
Description: Biological: Aldafermin (NGM282) Subcutaneous Injection
Study: NCT05023486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-G2-044 Combination therapy
Description: 1600 mg QD or 2100 mg QD
Study: NCT04932161

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titanium Granules
Description: After degranulation of the intrabony defect, titanium particles will be placed in the defect and will be sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyapatite
Description: After degranulation of the intrabony defect, hydroxyapatite will be placed in the defect and will be sutured.
Study: NCT04823702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldafermin
Description: Biological: Aldafermin (NGM282) Subcutaneous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldafermin
Description: Biological: Aldafermin (NGM282) Subcutaneous Injection
Study: NCT05909098

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: autologous NK cell
Description: autologous NK cell
Study: NCT05050604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline Alfoscerate 400mg
Description: Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Choline Alfoscerate 400mg
Description: Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
Study: NCT06415292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Winlevi (clascoterone) 1% cream
Description: Split face. Blinded study treatment product to be applied to the randomized half face
Study: NCT06549855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)
Description: 1. Sintilimab or Pembrolizumab 200mg intravenous injection, every 3 weeks~2. MA, 320mg/MPA, 500mg, po, once a day
Study: NCT06538077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Branched chain Amino acid
Description: The active drug BCAA supplement will be dispensed in a dose of 15 gm once daily x 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 MG
Description: Active drug rifaximin will be dispensed in a dose of 550mg twice daily x 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Both groups will be treated with will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Both groups will be treated with will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BCAA
Description: A placebo comparator of 15 gm of skimmed milk powder will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Rifaximin 550mg
Description: Identical placebo sugar pills will be used as a placebo.
Study: NCT05066581

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Live Chat
Description: Subjects from the intervention group will be able to ask for a medical intervention if needed with the phisycians from the sleep unit. After the following period, we expect to see better sleep habits in this group when compared to the no intervention one
Study: NCT05803863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myatro
Description: myopia control with 0.01% atropine drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myatro XL
Description: myopia control with 0.05% atropine drops
Study: NCT06395675

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ID NOW™
Description: The ID NOW™ CT/NG is an in vitro qualitative molecular assay for the rapid differential.~detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in urine, and self-collected vaginal swabs (SVS) in symptomatic and asymptomatic individuals.
Study: NCT05893771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Injection
Description: Ultrasound-guided genicular nerve block comparing Methylprednisolone combined with Bupivacaine to bupivacaine alone. All patients will undergo TKA and will receive spinal anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.5% Inj_#2
Description: Ultasound- guided genicular nerve block using 5 ml bupivacaine 0.5% in 15 ml saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hcl 0.5% Inj_#2
Description: Ultasound- guided genicular nerve block using 5 ml bupivacaine 0.5% in 15 ml saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.
Study: NCT05329480

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Creatine Monohydrate powder, 4 separate 5g doses per day for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin powder, 4 separate 5g doses per day for 7 days.
Study: NCT06655792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program on Mental Illness Stigma Reduction
Description: The intervention consists of an 8-session educational program designed to reduce stigma towards mental illness among primary healthcare providers. The program includes lectures and multimedia presentations on mental health, stigma, and its effects. It engages participants in role-playing exercises to simulate the experience of stigma and improve communication skills. Group discussions allow participants to reflect on personal beliefs and attitudes, and case studies provide real-world examples of stigma and intervention strategies. The program spans four days, with two sessions per day, each lasting 50-60 minutes.
Study: NCT06606002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group schema therapy
Description: Group schema therapy based on the model by Farrell and Shaw, which is complemented with separate group sessions for the participants\&#39; parents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: TAU typically comprises visits at the outpatient clinic with variable frequency and content
Study: NCT06605274

Intervention type: OTHER
Group type: OTHER
Intervention: Web-Based Education Program
Description: Before being discharged from the clinic, the women who experienced perinatal loss filled out the Personal Information Form, Perinatal Grief Scale, Edinburgh Postnatal Depression Scale, Beck Hopelessness Scale, and Stress Coping Styles Scale individually. The women were informed about the use of the website. The discharged women were contacted by phone, given the passwords of the birliktegücleniyoruz.com website, and invited to use the website for the five-week education program. Each week, only one session determined for that week was uploaded to the site. Participants who wished to do so were able to watch the uploaded sessions more than once. Retrospective sessions also remained accessible on the site. Each session lasted an average of 20-30 minutes. Women who completed five sessions were contacted by phone in the sixth week. Women filled out the PGS, EPDS, BHS, and SCSS online a second time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Before being discharged from the perinatology clinic, the women filled out the Personal Information Form, PGS, EPDS, BHS, and SCSS individually. Six weeks after discharge, the participants filled out the same measurement tools online again. During this process, the hospital's routine monitoring continued for the control group. The website was opened to the use of participants who wanted to use the site after the completion of the final tests.
Study: NCT06654505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paired Community Health Workers
Description: Community Health Workers will promote maternal and child health services as paired female and male
Study: NCT06661967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine spray
Description: Comparison of the success rate of endotracheal intubations between lidocaine spray and placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine spray
Description: Comparison of the success rate of endotracheal intubations between lidocaine spray and placebo
Study: NCT06660524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer
Description: Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guidelines for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
Study: NCT06661187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Description: Patients who received cryoanalgesia: patients subjects underwent arterial puncture. patients in the intervention group had a small plastic bag filled with 12 oz of crushed ice applied to the radial artery puncture site for 3 min (timed with a stopwatch) without external compression or massage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychological instructions
Description: Psychological interventions using verbal signals of the impending procedure, music distraction, visual distraction, and breathing interventions be used during arterial puncture in adults

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: No intervention deliver routine care
Study: NCT06658054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant analgesia
Description: Patients will receive adjuvant dexmedetomidine (25mcg) and dexamethasone (5mg) in addition to bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Description: Patient will receive standard ESPB with bupivacaine and normal saline
Study: NCT06662266

Intervention type: DEVICE
Group type: OTHER
Intervention: Induce XT™ is a mixture of human cortical bone fibers and microparticulates that have been processed into Natural Matrix Protein® (NMP®) to which cancellous bone microparticulates have been added
Description: Bone graft material is required for successful foot and ankle fusion surgery. Current bone grafting materials include autogenous bone, Augment Bone Graft and demineralized bone matrix (DBM), each of which have limitations.~Induce XT is a novel bone graft material that can potentially be used in foot and ankle fusions that may overcome some of these limitations.
Study: NCT06659016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin 3 g
Description: Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Uroxin 4G
Description: Dietary supplement of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of dietary supplement and fosfomycin
Description: Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months, combined with an oral formulation of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
Study: NCT06661278

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise tolerance test
Description: Clinical routine exercise tolerance test using an exercise treadmill, according to the arrhythmia protocol (15 minute protocol utilising increasing speed and incline with a 6 minute recovery)

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise tolerance test
Description: Clinical routine exercise tolerance test using an exercise treadmill, according to the arrhythmia protocol (15 minute protocol utilising increasing speed and incline with a 6 minute recovery)

Intervention type: OTHER
Intervention: Physical activity & heart rate monitoring
Description: Physical activity monitoring over two weeks using Actiheart and Pro-Diary monitors to record heart rate, heart rhythm, activities engaged in and estimated intensity of activities.

Intervention type: OTHER
Intervention: Physical activity & heart rate monitoring
Description: Physical activity monitoring over two weeks using Actiheart and Pro-Diary monitors to record heart rate, heart rhythm, activities engaged in and estimated intensity of activities.
Study: NCT06598514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Participants will use a 2% chlorhexidine perineal lavage following defecation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Water
Description: Participants will use a sterile water perineal lavage following defecation
Study: NCT06605820

Intervention type: OTHER
Intervention: None - Interview Only
Description: None - Interview Only
Study: NCT04885972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: Resiniferatoxin is a compound purified from natural sources.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zilretta
Description: Zilretta is an extended-release corticosteroid approved to manage osteoarthritis knee pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle solution
Study: NCT06042452

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic
Description: A saliva sample test will be undertaken by all participants in order to analyze their DNA for personalizing their recommendations. The Global Screening Array (GSA) will be used.
Study: NCT05322876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Hearts Family Program
Description: Participants will participate in a baseline health and knowledge screening, followed by a 6-week once-weekly class series, and 3- and 6-month follow-up health and knowledge screenings.
Study: NCT06606717

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Whey Protein
Description: 3 grams creatine + 30 grams whey protein
Study: NCT06513520

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Additional blood tube collection during routine blood sampling.

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Additional blood tube collection during routine blood sampling.
Study: NCT06476483

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIALOG+
Description: A person-centred and solution-focused intervention linked to the DIALOG outcome measure (a measure of patient experience and quality of life).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DIALOG
Description: An outcome measure consisting of 11 questions, with 8 related to quality of life and 3 items on treatment satisfaction. Patients can rate their satisfaction on a 7-point scale for each of the 8 life domains and 3 treatment aspects, resulting in scores for both quality of life and treatment satisfaction. The DIALOG scale does not provide any guidance for patient and clinician interactions.
Study: NCT06606717

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: 30 grams Whey Protein
Study: NCT06607536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calcium chloride surface treatment in mini implant
Description: 0.1M of Calcium Chloride were used to immersed the orthodontic mini implant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acid Etched
Description: Mini implant etched in Hydrochloric acid
Study: NCT05541666

Intervention type: BEHAVIORAL
Intervention: The Emotional Freedom Technique
Description: The Emotional Freedom Technique (EFT) is a method that uses cognitive functions and physical components (tapping acupuncture points) to bring about psychological changes. The Emotional Freedom Technique is a non-invasive procedure that uses acupuncture meridians. We stimulate these energy points by touching the 14 basic meridian points ın this technique. We make suggestions to our subconscious by repeating the setup sentence for the problem we want to solve. Thus, we try to solve the blockages in the meridians that prevent the flow of energy. Energy blockages disrupt the balance of the mind/body/energy system. This situation causes negative emotions such as stress, panic, fear, and sadness in the person. And with the effect of emotions, disturbances may occur in our physical body. When the energy blockage is removed, the person can feel positive emotions such as happiness, personal power, feeling good, understanding, and loving behavior.
Study: NCT06374589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop FiO2 controller
Description: Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Six hours period where the fraction of inspired oxygen (FiO2) delivered will be manually titrated by clinician based on SpO2 values obtained from the patient.
Study: NCT05999812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all trans Retinoic Acid
Description: ATRA orally 45 mg/m2 QD in 2 divided doses days 1-7, repeat every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab IV D1, 840 mg every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab IV D1, 10 mg/kg every 14 days
Study: NCT05130268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Dronedarone 400 mg twice daily in addition to usual care
Study: NCT06067984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study App
Description: An investigational prescription digital therapeutic in the form of a smartphone app.
Study: NCT06607224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental (Decision making guided by CGM)
Description: Patients use FSL2 and a smartphone. Libreview app will be used to assess interstitial glucose, alarms, and trend arrows, and LibreLinkUp app for research team. Concurrently, CG will be performed using the FreeStyle Optium Neo glucometer from Abbott. The nursing staff will be trained to manage and respond to alarms and trend arrows according to established protocols. The basal insulin adjustment protocol establishes with fasting and premeal targets between 140-180 mg/dL. For prandial insulin, corrective guidelines set according to each patient sensitivity factor, with additional adjustments for the intervention group based on trend arrows. The hypoglycemia alarm sets below 85 mg/dL. If activated, nursing staff will confirm the value via CG. If values are below 70 mg/dL, follow hypoglycemia protocol and if below 100 mg/dL with a descending trend arrow, 15 grams of slow-acting carbs. The hyperglycemia alarm will be set above 300 mg/dL and nurse inform investigators to make decisions.